Curcumin and proton pump inhibitors for functional dyspepsia: A randomised, double blind controlled trial
Issued Date
2023-01-01
Resource Type
ISSN
2515446X
eISSN
25154478
Scopus ID
2-s2.0-85172303305
Pubmed ID
37696679
Journal Title
BMJ Evidence-Based Medicine
Rights Holder(s)
SCOPUS
Bibliographic Citation
BMJ Evidence-Based Medicine (2023)
Suggested Citation
Kongkam P., Khongkha W., Lopimpisuth C., Chumsri C., Kosarussawadee P., Phutrakool P., Khamsai S., Sawanyawisuth K., Sura T., Phisalprapa P., Buamahakul T., Siwamogsatham S., Angsusing J., Poonniam P., Wanaratna K., Teerachaisakul M., Pongpirul K. Curcumin and proton pump inhibitors for functional dyspepsia: A randomised, double blind controlled trial. BMJ Evidence-Based Medicine (2023). doi:10.1136/bmjebm-2022-112231 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/90321
Title
Curcumin and proton pump inhibitors for functional dyspepsia: A randomised, double blind controlled trial
Author's Affiliation
Ramathibodi Hospital
Siriraj Hospital
Faculty of Medicine, Khon Kaen University
King Chulalongkorn Memorial Hospital
University of Liverpool
Thailand Ministry of Public Health
Johns Hopkins Bloomberg School of Public Health
Faculty of Medicine, Chulalongkorn University
Ratchaburi Regional Hospital
Chaophraya Abhaibhubejhr Hospital
Siriraj Hospital
Faculty of Medicine, Khon Kaen University
King Chulalongkorn Memorial Hospital
University of Liverpool
Thailand Ministry of Public Health
Johns Hopkins Bloomberg School of Public Health
Faculty of Medicine, Chulalongkorn University
Ratchaburi Regional Hospital
Chaophraya Abhaibhubejhr Hospital
Other Contributor(s)
Abstract
Objective: To compare the efficacy of curcumin versus omeprazole in improving patient reported outcomes in people with dyspepsia. Design: Randomised, double blind controlled trial, with central randomisation. Setting: Thai traditional medicine hospital, district hospital, and university hospitals in Thailand. Participants: Participants with a diagnosis of functional dyspepsia. Interventions: The interventions were curcumin alone (C), omeprazole alone (O), or curcumin plus omeprazole (C+O). Patients in the combination group received two capsules of 250 mg curcumin, four times daily, and one capsule of 20 mg omeprazole once daily for 28 days. Main outcome measures: Functional dyspepsia symptoms on days 28 and 56 were assessed using the Severity of Dyspepsia Assessment (SODA) score. Secondary outcomes were the occurrence of adverse events and serious adverse events. Results: 206 patients were enrolled in the study and randomly assigned to one of the three groups; 151 patients completed the study. Demographic data (age 49.7±11.9 years; women 73.4%), clinical characteristics and baseline dyspepsia scores were comparable between the three groups. Significant improvements were observed in SODA scores on day 28 in the pain (-4.83, -5.46 and -6.22), non-pain (-2.22, -2.32 and -2.31) and satisfaction (0.39, 0.79 and 0.60) categories for the C+O, C, and O groups, respectively. These improvements were enhanced on day 56 in the pain (-7.19, -8.07 and -8.85), non-pain (-4.09, -4.12 and -3.71) and satisfaction (0.78, 1.07, and 0.81) categories in the C+O, C, and O groups, respectively. No significant differences were observed among the three groups and no serious adverse events occurred. Conclusion: Curcumin and omeprazole had comparable efficacy for functional dyspepsia with no obvious synergistic effect.